Skip to content

Clinical evaluation of Kagamaasi thylam ( A siddha drug) in the management of childhood asthma (sooli kanam)

Clinical evaluation of kagamaasi thylam ( A siddha drug)in the management of sooli kanam (childhood asthma) in children

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/08/035372
Enrollment
30
Registered
2021-08-03
Start date
Unknown
Completion date
Unknown
Last updated
2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: Kagamaasi thylam: Kagamaasi thylam is given twice a time after food. 3ml for 5 to 7 years 5ml for 8to 12 years Control Intervention1: Not applicable: Not applicable

Sponsors

OPD and IPD Ayothidoss Pandithar Hospital National instititue of siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Children with any of the symptoms such as Cough Wheezing Shortness of breath Abdominal bloating Tightness of chest Loss of appetite are included

Exclusion criteria

Exclusion criteria: K/H/o Hemoptysis Active primary complex Congenital heart disease Pneumonia Status asthmaticus Any other chronic illness are excluded

Design outcomes

Primary

MeasureTime frame
Efficacy of the trail drug is measured by peak expiratory flow meter Improvement in the clinical symptoms by using PASS scoreTimepoint: 45 days

Secondary

MeasureTime frame
Reduction in the recurrence of the disease and improvement in the quality of life of childrenTimepoint: Before and after treatment

Countries

India

Contacts

Public ContactDr M Meenakshi Sundaram

National Institute of Siddha

mmssiddha@rediffmail.com9444214582

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026